Novel Approaches to Colon Targeted Drug Delivery System: A Review.
Nemade Mahesh S*, Chaudhari Rajesh Y, and Patil Vijay R
TVES’s HLMC College of Pharmacy, Faizpur, India.
Received date: 25/02/2014 Accepted date: 17/03/2014 Published date: 11/03/2014
Targeted drug delivery to the colon is being explored not only for local colonic pathologies, but also for systemic delivery of drugs like proteins and peptides. Local delivery could, allow topical treatment of inflammatory bowel disease. Treatment could be made more effective for drugs to be targeted directly on the colon site and systemic side effects could be reduced. Colon specific systems might also allow oral administration of peptide and protein drugs, which are normally degraded in the upper parts of the gastrointestinal tract. The treatment of disorders of the large intestine (colon), such as Colon cancer, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) i.e. Ulcerative colitis and Crohn’s disease, Diverticulitis and other colon diseases, where it is necessary to attain a high concentration of active therapeutic agent, may be efficiently achieved by colon specific delivery. This is also a potential site for the treatment of diseases sensitive to circadian rhythms such as asthma, angina, hypertension and arthritis. Primary approaches for colon specific drug delivery (CDDS), which includes prodrugs, pH and time dependent systems and microbially triggered drug delivery system achieved limited success and having limitations. Newly developed CDDS, which includes pressure controlled colonic delivery capsules (PCDCS) and osmotic controlled drug delivery are unique in terms of achieving in-vivo site specificity and feasibility of manufacturing process. The focus of this review is to provide detailed insight into the various colon diseases, approaches used to target the therapeutic agents specifically to the colon.